MX2021003599A - Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion. - Google Patents

Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion.

Info

Publication number
MX2021003599A
MX2021003599A MX2021003599A MX2021003599A MX2021003599A MX 2021003599 A MX2021003599 A MX 2021003599A MX 2021003599 A MX2021003599 A MX 2021003599A MX 2021003599 A MX2021003599 A MX 2021003599A MX 2021003599 A MX2021003599 A MX 2021003599A
Authority
MX
Mexico
Prior art keywords
rpl554
hfa
inhalation
administration
pharmaceutical compositions
Prior art date
Application number
MX2021003599A
Other languages
English (en)
Spanish (es)
Inventor
Peter Lionel Spargo
Phillip A Haywood
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of MX2021003599A publication Critical patent/MX2021003599A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021003599A 2018-10-09 2019-10-09 Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion. MX2021003599A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (1)

Publication Number Publication Date
MX2021003599A true MX2021003599A (es) 2021-05-28

Family

ID=64394831

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003599A MX2021003599A (es) 2018-10-09 2019-10-09 Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion.
MX2024001499A MX2024001499A (es) 2018-10-09 2021-03-26 Composiciones farmacéuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administración por inhalación.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024001499A MX2024001499A (es) 2018-10-09 2021-03-26 Composiciones farmacéuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administración por inhalación.

Country Status (27)

Country Link
US (2) US20210379053A1 (enExample)
EP (2) EP3960157A1 (enExample)
JP (2) JP7578587B2 (enExample)
KR (1) KR20210073532A (enExample)
CN (1) CN112912064B (enExample)
AU (1) AU2019358585B2 (enExample)
BR (1) BR112021006712A2 (enExample)
CA (1) CA3113167A1 (enExample)
CY (1) CY1124943T1 (enExample)
DK (1) DK3820446T3 (enExample)
ES (1) ES2899744T3 (enExample)
GB (1) GB2578093B (enExample)
HR (1) HRP20220053T1 (enExample)
HU (1) HUE057780T2 (enExample)
IL (1) IL282032A (enExample)
LT (1) LT3820446T (enExample)
MX (2) MX2021003599A (enExample)
MY (1) MY207302A (enExample)
PH (1) PH12021550767A1 (enExample)
PL (1) PL3820446T3 (enExample)
PT (1) PT3820446T (enExample)
RS (1) RS62775B1 (enExample)
SG (1) SG11202102567UA (enExample)
SI (1) SI3820446T1 (enExample)
SM (1) SMT202200044T1 (enExample)
WO (1) WO2020074894A1 (enExample)
ZA (1) ZA202102039B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
KR20250087621A (ko) * 2022-10-28 2025-06-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60005493T2 (de) 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
MX345802B (es) * 2010-08-09 2017-02-16 Verona Pharma Plc * Forma cristalina de compuesto pirimido [6, 1-a] isoquinolin-4-ona.
RU2697862C2 (ru) * 2012-02-28 2019-08-21 Айсьютика Холдингз Инк. Ингаляционные фармацевтические композиции
RU2666624C2 (ru) * 2013-03-15 2018-09-11 ВЕРОНА ФАРМА ПиэЛСи Комбинация лекарственных средств
PL3231444T3 (pl) * 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
RU2699995C2 (ru) * 2014-09-15 2019-09-12 ВЕРОНА ФАРМА ПиэЛСи Жидкая ингаляционная композиция, содержащая rpl 554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
SG11202102567UA (en) 2021-04-29
SI3820446T1 (sl) 2022-01-31
JP2024113096A (ja) 2024-08-21
AU2019358585A1 (en) 2021-04-15
US20250049781A1 (en) 2025-02-13
HUE057780T2 (hu) 2022-06-28
US20210379053A1 (en) 2021-12-09
JP7578587B2 (ja) 2024-11-06
EP3960157A1 (en) 2022-03-02
JP2022513566A (ja) 2022-02-09
SMT202200044T1 (it) 2022-05-12
ES2899744T3 (es) 2022-03-14
LT3820446T (lt) 2021-12-10
MY207302A (en) 2025-02-15
CN112912064A (zh) 2021-06-04
AU2019358585B2 (en) 2025-01-16
RS62775B1 (sr) 2022-01-31
EP3820446B1 (en) 2021-11-03
DK3820446T3 (da) 2021-12-06
CA3113167A1 (en) 2020-04-16
GB2578093A (en) 2020-04-22
BR112021006712A2 (pt) 2021-07-27
GB201816447D0 (en) 2018-11-28
CN112912064B (zh) 2025-02-14
PL3820446T3 (pl) 2022-03-14
EP3820446A1 (en) 2021-05-19
WO2020074894A1 (en) 2020-04-16
MX2024001499A (es) 2024-02-27
CY1124943T1 (el) 2023-01-05
IL282032A (en) 2021-05-31
PT3820446T (pt) 2021-12-03
ZA202102039B (en) 2022-08-31
GB2578093B (en) 2020-11-18
PH12021550767A1 (en) 2021-10-04
KR20210073532A (ko) 2021-06-18
HRP20220053T1 (hr) 2022-04-15

Similar Documents

Publication Publication Date Title
MX2021003599A (es) Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion.
MX2021009476A (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
CL2018003604A1 (es) Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983)
AR130238A2 (es) Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de un envase de aerosol asociado
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
MX2022005380A (es) Composiciones que comprenden colina.
UY35963A (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
CO6290637A2 (es) Composicion farmaceutica que comprende aclidinio en forma de un polvo seco de una sal farmaceuticamente aceptable mezclado con un vehiculode polvo seco farmaceuticamente aceptable
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
MX2016010541A (es) Composiciones de canabinoide y usos.
NO20083375L (no) Farmasoytisk formulering for aerosoler, omfattende to eller aktive midler og minst et overflate aktivt middel
MX338685B (es) Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida.
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
BR112016025205A2 (pt) método para minimizar névoa de aerossol com base em enzima usando um sistema de aspersão a pressão
BR112018011266A2 (pt) ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica?
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
UY36058A (es) “dispositivo inhalador accionado por la respiración
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
MX375427B (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion
AR089302A1 (es) Un medicamento inhalable
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas
BR112012008983A2 (pt) "formulação medicinal em suspensão, composição farmacêutica, produto, uso de cromolina sódica,e, método para aumentar a estabilidade de uma formulação medicinal em suspensão de aerossol."
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion